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Cancer stem cells are likely to play critical roles in
metastasis, therapy resistance, and recurrence of
hematological and solid malignancies. It is well known
that the stem cell niche plays a key role for
asymmetric division and homeostasis of normal stem
cells, whereas cancer stem cells seem to use these
niches. Among many pathways involved in self-
renewal of cancer stem cells, nuclear factor-kappa B
(NF-κB) signaling has been documented to promote
their expansion in a cell-autonomous fashion. A recent
study, however, suggests that paracrine NF-κB
activation promotes the expansion of cancer stem
cells through the activation of Notch in basal-type
breast cancer cells.NF-κB activation is not essential in CSCs themselves duringNuclear factor-kappa B (NF-κB) pathways, including
canonical (activated by IκB kinase (IKK) α/β/γ complex
and activation of RelA/p50) and non-canonical
(activated by NF-κB-inducing kinase (NIK) and IKKα,
activation of RelB/p52) pathways, link inflammation and
cancer in a variety of animal models. NF-κB pathways
are also important for normal mammary gland develop-
ment as well as for breast cancer tumorigenesis and
cancer stem cell biology, and previous studies specifically
emphasize the cell-autonomous role of NF-κB activation
in breast cancer stem cells (CSCs) [1]. Based on animal
models, however, protumorigenic inflammatory signaling
often works in a feed-forward manner. For example, the
NF-κB activation in the tumor microenvironment
induces the production of various cytokines which, in
turn, activate NF-κB or other pro-carcinogenic pathways
in cancer cells to stimulate cell survival and proliferation
and to enhance the production of chemokines, leading* Correspondence: weizhou-zhang@uiowa.edu; sergey.grivennikov@fccc.edu
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[2]. Given the complexity of the tumor microenviron-
ment, whether any paracrine signals activated by NF-κB
contribute to self-renewal of CSCs in trans remains
unknown.
An elegant study by Yamamoto and colleagues [3] re-
cently identified a non-cell-autonomous NF-κB activation
for the expansion of CSCs in basal-type breast cancer, one
of the most malignant types associated with early relapse.
Although CSCs can secrete factors regulating their own
maintenance in an autocrine fashion, Yamamoto and col-
leagues demonstrated that non-CSC cancer cells, tumor-
associated macrophages, and fibroblasts provide a support-
ive microenvironment for CSCs by producing Jagged 1
(JAG1), one of the five known ligands in the Notch path-
way, which plays a critical role in CSC self-renewal. While
this process, it is the TNFα-, NIK-, and IKKβ-dependent
activation of NF-κB which drives JAG1 production from
auxiliary cells. Somewhat surprisingly, IL-6 and −8 (well-
known targets of the NF-κB pathway and suggested regula-
tors of CSCs [4,5]) were not involved in this paracrine
signaling and the expansion of CSCs. The authors further
applied gene set enrichment analysis of extensive datasets
to find a unique correlation between the NF-κB-JAG1 axis
in ‘basal’ but not in any other subtypes of breast cancer.
Whereas Yamamoto and colleagues demonstrated the
role of JAG1 in CSC homeostasis of the basal type of
breast cancer, other reports identified that estrogen
receptor (ER)low/− CSCs can be regulated by Notch acti-
vation in ER+ breast cancer in an estrogen-dependent
manner [6]. The evil connection between Notch and
HER2 is also well documented in HER2+ [7] and in ER+
luminal breast cancer without HER2 amplification where
Notch, in concert with receptor activator of NF-κB
(RANK) signaling, upregulates HER2 transcription and
regulates expansion of HER2+ CSCs [8,9]. Although the
importance of paracrine Notch signaling in HER2+ CSCs
has yet to be demonstrated, it is plausible that paracrine
Notch activation may be a common regulatory theme
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inforcing the notion that tumor microenvironment aids
tumor progression in general and assists self-renewal of
CSCs in particular. The mechanistic role of Notch in
CSCs can be potentially explained by its ability to induce
an epithelial-mesenchymal transition (EMT), a known
biological process contributing to the development of
CSCs [10]. While the requirement for Notch signaling
may be uniform, it is quite possible that distinct path-
ways that induce the expression of Notch ligands differ
for CSCs and non-CSCs in different types of cancer. For
example, the IL-6/STAT3 pathway has been shown to
induce JAG1 expression and promote malignant stem
cell growth [11]. The link between NF-κB activation and
JAG1 expression appears to be broken in claudin-low
breast cancer, a recently identified molecular subtype
with active NF-κB, EMT, and CSC signatures, but these
parameters demonstrated no correlation with JAG1
expression [3]. Therefore, other pathways may be neces-
sary for NF-κB-dependent and -independent JAG1 tran-
scription. These data also explain the observation that
TNFα failed to enhance JAG1 expression in luminal and
claudin-low breast cancer cells, even though it strongly
induced NF-κB activation. It will be interesting to find
out the identity of additional signals, which cooperate
with or substitute for NF-κB to induce JAG1 expression
in basal breast cancer.
The crosstalk between NF-κB and Notch pathways is
quite complex and depends on the exact pathophysio-
logical context. Paracrine activation of Notch signaling
by NF-κB-dependent JAG1 expression has been previ-
ously shown during B-cell activation [12].
Likewise, several cell types within the tumor micro-
environment may activate NF-κB and produce JAG1, de-
pending on the local context and exact identity of
NF-κB-inducing stimuli. Unfortunately, the lack of
simple markers makes it hard to detect CSCs in situ and
find out their adjacent cells providing Notch ligands by
current immunostaining techniques. Nonetheless, estab-
lishing the mechanistic connection between NF-κB and
Notch pathways diversifies potential targets for thera-
peutic intervention. Long-term inhibition of canonical
IKKβ/NF-κB signaling may be problematic because of
severe immune complications [13]. There is no specific
NIK inhibitor for pharmaceutical use yet. Because of its
important role in both canonical and non-canonical
NF-κB pathways in the immunity and the severe pheno-
type of NIK-deficient mice [14], inhibiting NIK may also
cause severe side effects. Denosumab, a humanized
monoclonal antibody neutralizing cytokine RANKL
(receptor activator of nuclear factor kappa-B ligand) and
inhibiting RANKL/RANK-mediated NIK/IKKα activa-
tion [15] and approved to treat breast cancer patients
with bone metastasis, represents a potential agent forneoadjuvant therapy of RANK-positive basal breast can-
cer to target CSCs. Other selections include agents that
target Notch signaling, such as γ-secretase inhibitors
and monoclonal antibodies targeting ligands or receptors
[16]. Toxicity has to be carefully evaluated because of
their critical role in normal tissue homeostasis. Combin-
atory treatment with classic dose-dense chemotherapy
should be considered when treating basal-type breast
cancer to target both the bulk tumor cells and CSCs.
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